Parsing Failure News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article NEW YORK, April 26, 2021 /PRNewswire/  Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. ( CytoDyn or the Company ) (OTCMKTS: CYDY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether CytoDyn and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On March 5, 2021, CytoDyn issued a press release providing an update on its product Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications. The press release stated, in part, that the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients. Although the press release touted purportedly

New yorkUnited statesFrance generalLos angelesAbrahaml pomerantzPaul santosRoberts willoughbyCytodyn incPomerantz firmSeeking alphaParsing failureபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்பிரான்ஸ் ஜநரல்லாஸ் ஏஞ்சல்ஸ்பால் சாண்டோஸ்